BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8725130)

  • 1. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology.
    Ross JS; Cheung C; Sheehan C; del Rosario AD; Bui HX; Fisher HA
    Diagn Cytopathol; 1996 Jun; 14(4):310-5. PubMed ID: 8725130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
    Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
    Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder.
    Lazzeri M; Vannucchi MG; Spinelli M; Bizzoco E; Beneforti P; Turini D; Faussone-Pellegrini MS
    Eur Urol; 2005 Oct; 48(4):691-8. PubMed ID: 15992990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma.
    Mai KT; Elmontaser G; Perkins DG; Yazdi HM; Stinson WA; Thijssen A
    BJU Int; 2004 Sep; 94(4):544-7. PubMed ID: 15329109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
    Messing EM
    Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [E-CD expression and its clinical significance in human bladder carcinoma].
    Hao Y; Zhao C; Li X; Teng M
    Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):459-61. PubMed ID: 11829888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
    Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA
    Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens.
    Cheng L; Reiter RE; Jin Y; Sharon H; Wieder J; Lane TF; Rao J
    J Urol; 2003 Jun; 169(6):2094-100. PubMed ID: 12771726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
    Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
    Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytology of transitional cell carcinoma of the urinary bladder.
    Kern WH
    Acta Cytol; 1975; 19(5):420-8. PubMed ID: 1058612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
    Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
    Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
    Sun W; Herrera GA
    Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fascin stain as a potential marker of invasiveness in carcinomas of the urinary bladder: a retrospective study with biopsy and cytology correlation.
    McKnight R; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2011 Sep; 39(9):635-40. PubMed ID: 20949550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
    Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
    Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.